Richard Lee Lab retweeted
Holy cow! Open call for a Researcher position (MSc or PhD, no post-doc experience needed). This will person will be a part of the Pediatric Dependencies Project - a collaboration between @broadinstitute, @DFBC_PedCare and @StJudeResearch! Cool, right?
talent.stjude.org/careers/jo…
Richard Lee Lab retweeted
Another development milestone for our program to potentially treat coenzyme-A (CoA) deficiencies! We recently dosed the first patient in our PA/MMA clinical trial. $BBIO bit.ly/3PxmJQO
Richard Lee Lab retweeted
St. Jude is built on a strong foundation of collaborative interactions spanning many disciplines, including biomedical sciences, global child health and clinical investigations. Learn more. ow.ly/FUfa50IPeER
Richard Lee Lab retweeted
Looking forward to speaking on new approaches to antibiotic discovery at the GARDP webinar. revive.gardp.org/new-approac… @gardp_amr @StJudeResearch
Richard Lee Lab retweeted
.@ZelenskyyUa's tv address to the Russian (!) people might be the most moving speech that I've ever seen in my entire life. The whole world needs to see, understand and share this crucial Ukrainian message.
#StandWithUkraine #Ukraine #Україна #Russia #Россия
President Zelenskyy's speech to the Russian people
Ukrainian President Volodymyr Zelenskyy's plea to the Russian people in video remarks posted early on Feb. 24 local time with English subtitles.
Richard Lee Lab retweeted
Proud to hear my former trainee Julian Hurdle was promoted to full professor at Texas A&M Health Science Center. Congrats Julian, you are an outstanding scientist.bit.ly/3IjDBaZ #blackinchem
Richard Lee Lab retweeted
This…
NEW—An estimated 1.2 million people died in 2019 from antibiotic-resistant bacterial infections, more deaths than HIV/AIDS or malaria.
#GRAMPaper reveals the scale of antimicrobial resistance (#AMR), now a leading cause of death worldwide: hubs.li/Q012sG-t0 #AMRSOS
Richard Lee Lab retweeted
Congrats to Stephanie Reeve @reeve_steph for winning the best presentation award at the St Jude Chemical Biology Therapeutics dept retreat and receiving the much-coveted CBT belt. I am lucky to have such a talented postdoc in my lab. @stjuderesearch @ansarilab @richardleelab
New paper about a surprisingly difficult TB drug target to ligand with non-peptides bit.ly/3owDZvg
Richard Lee Lab retweeted
LipE rocks. Happy to report the details on how our LipE driven hit to lead program for PanK produced our initial preclinical lead.
doi.org/10.1016/j.bmc.2021.1…
Richard Lee Lab retweeted
Please join us for the Advances in Antibacterial Discovery symposium on Dec 3. The conference is hosted by @richardleelab and features a wonderful speaker lineup. Register here: bit.ly/3yNSz3b @stjuderesearch
Richard Lee Lab retweeted
Organic acidemias are a group of inherited metabolic disorders with significant morbidity and mortality. New data published today by @stjuderesearch in @ScienceTM may support the potential for our investigational therapy to help these patients in need. bit.ly/3hxVQy8
Big day in the Lee lab, 5000th molecule advances to biological testing and is celebrated with ice cream cake. I want to thank the hard work of all those who have synthesized and tested these unique molecules over the past twenty years.
We have a great new lab research website; enjoy. stjude.org/research/labs/lee…
Richard Lee Lab retweeted
Please save the date for the Advances in Antibacterial Discovery virtual mini-symposium. It is free to attend and I am delighted with the line-up of speakers. It should be a great day. bit.ly/3yNSz3b
Richard Lee Lab retweeted
Who doesn't love a beautiful cover? Congratulations to Marcus Fischer @TheFischerLab, Shanshan Y. C. Bradford, and Maddie Rice @_maddvisuals!
Don't miss the article bit.ly/Fischer_Media and the manuscript rsc.li/2WLrAbk
@StJudeResearch
Richard Lee Lab retweeted
Bob's Med Chem Fact of the Day
Drugs have unique target product profiles (TPP), with different safety and PK needs.
Thus, don't blindly use the line "this functional group is in approved drugs" in discussions, without understanding of respective TPPs, synthetic challenges, etc.























